Abstract: A better understanding of the molecular and cellular determinants that influence the pathology of Parkinson's disease (PD) is essential for developing effective diagnostic, preventative and therapeutic strategies to treat this devastating disease. A number of post-translational modifications to a-syn are present within the Lewy bodies in the brains of affected patients and transgenic models of PD and related disorders. However, whether disease-associated a-syn post-translational modifications promote or inhibit a-syn aggregation and neurotoxicity in vivo remains unknown. Herein, we summarize and discuss the major disease-associated post-translational modifications (phosphorylation, truncation and ubiquitination) and present our current understanding of the effect of these modifications on a-syn aggregation and toxicity. Elucidating the molecular mechanisms underlying post-translation modifications of a-syn and the consequences of such modifications on the biochemical, structural, aggregation and toxic properties of the protein is essential for unravelling the molecular basis of its function(s) in health and disease. Furthermore, the identification of the natural enzymes involved in regulating the post-translational modifications of a-synuclein will yield novel and more tractable therapeutic targets to treat PD and related synucleinopathies.
therapeutic strategies to treat this devastating dis ease. Current strategies offer little more than tran sient symptomatic relief. Evidence from genetics, pathology, animal modelling, cell culture and in vitro biochemical and biophysical studies supports the hypothesis that a-synuclein (a-syn) plays a cen tral role in the pathogenesis of PD and several other neurodegenerative diseases, collectively referred to as 'synucleinopathies'. Although a-syn has emerged as a viable therapeutic target, the molecular and cellular determinants involved in initiating and/or propagating a-syn aggregation and toxicity and the relationship between these processes and disease progression remain poorly understood. In PD, sev eral post-translational modifications of a-syn are associated with the formation of Lewy bodies (LB) in the brains of affected patients and of transgenic (TG) models of PD and other synucleinopathies. However, whether disease-associated a-syn post translational modifications such as phosphorylation, truncation, ubiquitination and nitration promote or inhibit a-syn aggregation and neurotoxicity in vivo remains unknown. This understanding is critical to elucidate the role of a-syn in the pathogenesis of PD and to develop therapeutic strategies for PD. There fore, characterizing the molecular mechanisms underlying post-translation modifications of a-syn and the consequences of such modifications on the biochemical, structural, aggregation and toxic prop erties of the protein is essential for unravelling the molecular basis of its function(s) in health and dis ease. Furthermore, identification of the natural enzymes (e.g. kinases and phosphatases) involved in regulating a-syn post-translational modifications will yield novel and more effective therapeutic tar gets to treat PD and related synucleinopathies.
Structural and biochemical properties of a-syn
The sequence of a-syn can be divided into three domains with different features (Fig. 1a) . The Fig. 1 . a-syn structure and molecular mechanism of its oligomerization and fibrillogenesis. (a) Schematic representation of a-syn, where the N-terminal repeats (KTKEGV) are represented in blue; they partially overlap with the core domain (white). The pathogenic variants associated with familial forms of PD alter the N-terminus of a-syn and enhance its propensity to form protofibrils (A30P) or mature fibrils (E46K and A53T). (b) Illustration of the molecular steps involved in a-syn oligomerization and fibrillogenesis leading to Lewy body formation (adapted from Lashuel and Lansbury, 2006) . N-terminal region, comprising amino acids 1-60, contains four 11 residue imperfect repeats with a highly conserved hexameric motif (KTKEGV). The central region, comprising residues 61-95, also known as the non-amyloid component region (NAC), is composed of predominantly hydropho bic residues and is essential for a-syn fibrillization and LB formation. The C-terminal region (residues 96-149) is highly enriched in acidic (glutamate and aspartate) and proline residues and exists in a dis ordered conformation in the monomeric as well as the oligomeric and fibrillar forms of a-syn (Bertini et al., 2007; Wu et al., 2008) . The C-terminus of a syn has been proposed to function as a solubilizing domain and contributes to a-syn's thermostability. The C-terminal region of a-syn has been implicated in the majority of a-syn interactions with proteins Fernandez et al., 2004; Giasson et al., 2003; Jensen et al., 1999) , metal ions (Brown, 2007; Paik et al., 1999) and other ligands (e.g. dopamine and polyamines) and contains the majority of post-trans lational modification sites. a-Synuclein interactions with the microtubule-associated protein tau, brainspecific p25a and FKBP-type peptidyl-prolyl cis-trans isomerases have all been mapped to the C-terminal region encompassing residues 110-140, suggesting that the C-terminus of a-syn plays a critical role in modulating the stability, structure, aggregation and function of the protein in vivo . In solution, a-syn (wild type, WT, A30P, E46K and A53T) exists as an ensemble of disordered conformations (Weinreb et al., 1996) . However, in the presence of lipids, the N-terminal region adopts an a-helical conformation. Several factors have been shown to contribute to triggering the oligomerization and fibril formation by a-syn, including high protein concentrations, mutations, post-translational modifications and interactions with specific metals (Brown, 2007; Paik et al., 1999) and small molecules . Fibril formation by a-syn proceeds through series of discrete oligomeric intermediates, known as protofibrils of different sizes and morphologies, including spherical, annular and chain-like struc tures (Fig. 1b) .
The rate of a-synuclein fibrillization is affected by several factors that may be relevant to PD Several post-translational covalent modifications have been described for a-syn, including serine and tyrosine phosphorylation, ubiquitination, nitration, enzymatic cross-linking (e.g. tissue transglutaminase) and C-terminal truncation, some of which correlate well with PD (Fig. 2) . In this section we will review the most commonly observed post-translational disease-associated modifications. We will present an overview of the current understanding of their role in disease pathogenesis on the basis of published in vitro and in vivo studies aimed at identifying the sites of modifications, the enzymes involved and the con sequences of modulating these modifications on the structure, aggregation, membrane binding and toxicity of a-syn.
Phosphorylation
Increasing evidence from pathologic, genetic, ani mal model, biochemical and biophysical studies suggests that phosphorylation of a-syn at one or multiple sites may play an important role in regulat ing its structure, membrane binding, oligomeriza tion, fibril formation, LB formation and neurotoxicity in vivo (Anderson et al., 2006; Fujiwara et al., 2002) . The first evidence demon strating phosphorylation of a-syn emerged from immunohistochemical and biochemical studies by Iwatsubo and colleagues and was supported later by many studies. Using a phospho-specific antibody and mass spectrometry, they demonstrated that the majority of a-syn within LB and inclusions isolated from brains of patients who died of PD, multiple system atrophy (MSA), dementia with Lewy bodies (DLB) and other synucleinopathies is phosphory lated at serine 129 (S129-P) (Anderson et al., 2006; 118 α-Synuclein: Post-translational modifications Most studied a-syn post-translational modifications reported on the basis of their identification in LB. All the modifications identified thus far, including phosphorylation, truncation, nitration and covalent cross-linking by tissue transglutaminase, occur at and/or involve the C-terminal region of the protein. Only ubiquitination (mono-, di-and tri-) is restricted to the lysine residues in the N-terminal region of the protein comprising residues 1-36. Fujiwara et al., 2002; Kahle et al., 2000; Okochi et al., 2000; Takahashi et al., 2003) . Subsequent cell culture studies demonstrated that a-syn is con stitutively phosphorylated at S87 and S129. Since then S129-P has emerged as a defining hallmark of PD and related synucleinopathies (Anderson et al., 2006; Fujiwara et al., 2002; Okochi et al., 2000; Takahashi et al., 2003) and is consistently observed in a-syn inclusion formed in cellular and animal models over-expressing WT or mutant a-syn (Chen and Feany, 2005; Lo Bianco et al., 2002; Neumann et al., 2002; Takahashi et al., 2003; Yamada et al., 2004) . Recent studies from our group demonstrated that a-syn is phosphorylated at S87 in vivo and within LB. The level of S87-P is increased in brains of TG models of synucleinopa thies and human brains from Alzheimer's disease (AD), DLB and MSA patients . A recent report by Feany and colleague demonstrated that a-syn is also phosphorylated at tyrosine 125 (Y125-P) and that phosphorylation at tyrosine residues Y125, Y133 and Y135 suppresses S129-P-induced aggregation and toxicity. These studies demonstrate the presence of multiple phos phorylation sites within a-syn and suggest potential cross-talk between the different modified sites.
All potential phosphorylation sites in a-syn are highly conserved A close examination and comparison of the amino acid sequences of all synucleins from humans and other species reveals that the majority of potential a-syn phosphorylation sites (4 serine, 10 threonine, 4 tyrosine residues, Fig. 3b ) are highly conserved in all species, suggesting that phosphorylation at one or multiple sites may play important roles in reg ulating a-syn function in health and disease.
Considering all a-syn phosphorylation sites identi fied in vivo [S129 (Chen and Feany, 2005; Fujiwara et al., 2002) , S87 and Y125 (Chen et al., 2009) ] and in vitro [S87 (Kim et al., 2006; Okochi et al., 2000) ; S129 (Chen and Feany, 2005; Fujiwara et al., 2002; Kim et al., 2006; Okochi et al., 2000; Pronin et al., 2000; Takahashi et al., 2003) and Y125, Y133 and Y136 (Ahn et al., 2002; Ellis et al., 2001; Nakamura et al., 2001; Negro et al., 2002; Takahashi et al., 2003) ], it is striking that all these sites cluster at the C-terminal region of a-syn spanning residues 120-140. Only S87 lies in the hydrophobic NAC region of a-syn, which is essential for a-syn aggregation and fibrillogenesis (El-Agnaf et al., 1998) . These findings suggest important roles for these modifications in regulat ing protein-protein, protein-ligand and proteina b Fig. 3 . a-syn phosphorylation in normal and pathological conditions. (a) Schematic depiction highlighting all the potential phosphorylation sites in a-syn: serine (S), threonine (T) and tyrosine (Y). When phosphorylation of the residue has been reported, the corresponding known kinases are indicated; the sites phosphorylated in human are listed in the upper part of the schema. (b) Multiple sequence alignment of a-syn generated by MUSCLE (version 3.6), in which serine, threonine and tyrosine residues are shown in color; note their high level of conservation trough mammals as only serine 87 is not preserved in rodents. 120 metal interactions, which have been mapped and shown to be mediated by the C-terminal domain of a-syn (see below).
Unravelling the role of phosphorylation in modulating the physiological and pathogenic activities of a-syn requires identification of the kinases and phosphatases involved in regulating its phosphorylation in vivo Although the exact kinases and phosphatases responsible for regulating a-syn phosphorylation at S129 in vivo are still not known, a series of in vitro and cell culture-based studies have identified a num ber of kinases, which phosphorylate a-syn at S129 and/or S87, including casein kinase I (CKI) (S87 and S129), casein kinase II (CKII) (S129) (Okochi et al., 2000) and the G protein-coupled receptor kinases (GRKs 1, 2, 5 and 6; S129) (Pronin et al., 2000) , LRRK2 (leucine-rich repeat kinase 2) (S129) (Qing et al., 2009 ) and PLKs (polo-like kinases) (S129) (Inglis et al., 2009; Mbefo et al., 2010) (Fig. 3a) . Tyrosine phosphorylation has also been reported at Y125 by Fyn (Nakamura et al., 2001) , Syk (Negro et al., 2002) , Lyn (Negro et al., 2002) , cFrg (Negro et al., 2002) and Src tyrosine kinases (Ellis et al., 2001) , with Syk (Negro et al., 2002) also phosphorylating at Y133 and Y136.
Phosphorylation at S129 and/or S87 alters the conformation of monomeric a-syn and inhibits its fibrillization in vitro Current cellular and in vivo studies aimed at dissect ing the functional consequences of phosphorylation at serine, threonine or tyrosine residues mainly rely on genetic approaches to block (e.g. replacing serine/ threonine with alanine, S/T ! A, or tyrosine with phenylalanine, Y ! F) or mimic constitutive phos phorylation (e.g. replacement of serine with gluta mate or aspartate, S ! E/D). The structural and electrostatic similarities between glutamate/aspar tate (net charge of -1) and phosphoserine (net charge of -2) suggest that this type of substitution represents a reasonable approach to mimic constitutive phos phorylation at specific serine residues. However, detailed studies from our group have shown that S ! D/E substitutions do not reproduce all aspects of phosphorylation. For example, structural compar isons of the phosphomimics S129D/E with S129-P using nuclear magnetic resonance (NMR) indicate that phosphorylation at S129 and S87 increases the hydrodynamic radius of a-syn to a value comparable to that observed for the WT protein in 8 M urea. In addition, paramagnetic relaxation enhancement of amide protons observed with the help of a spin label attached to residue 18 showed that long-range interactions between the N-and the C-terminal domains of a-syn are attenuated upon phosphoryla tion at S129 and S87. On the other hand, mutation of S129 and S87 to glutamate (S129E and S87E) or aspartate (S129D and S87D) does not lead to an extended conformation of monomeric a-syn. This result suggests that mutation of S ! D/E cannot fully mimic the effect of phosphorylation on the structure and dynamics of a-syn. The extent of fibril formation by the phosphomimics S129E/S129D is similar to that of the WT a-syn, whereas phosphor ylation at S129 (S129-P) consistently inhibits a-syn fibrillization. On the other hand, S ! D/E substitu tion at S87 reproduces the effect of phosphorylation on a-syn aggregation at this residue, that is both substitutions inhibit the fibrillization of a-syn in vitro. However, phosphorylation at S87, but not the S87D mutation, increases the hydrodynamic radius of a-syn and influences its binding to membranes.
Together, these studies demonstrate that phosphor ylation of a-syn at S129 and/or S87 significantly inhi bits its aggregation (Paleologou et al., 2008 Waxman and Giasson, 2008) and that the S ! D/E substitutions do not reproduce all aspects of phos phorylation. Therefore, the results obtained with these mimics should be interpreted with caution.
Does phosphorylation promote or prevent a-synuclein aggregation in vivo?
To answer this question, one must be able to modulate the level of phosphorylation in vivo.
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This modulation can be achieved by co-expression of a-syn and the relevant kinase or by comparing the effect of over-expressing the WT protein to the mutants designed to mimic (S129D) or abolish phosphorylation (S129A)(see Table 2 ). Although in vitro biophysical studies have clearly shown that replacement of serine by glutamate or aspartate does not reproduce all aspects of phosphorylation, the use of these mutants remains the only option for elucidating the role S129 phosphorylation in regulating a-syn aggregation and toxicity in vivo, especially given the lack of knowledge of efficient kinases that phosphorylate a-syn at this residue. In the next sections, we will present an overview of the findings from different in vivo studies aimed at elucidating the consequences of S129 phosphorylation.
GRK2-mediated phosphorylation at S129 or substitution of serine with aspartate (S129D) promotes a-syn oligomerization but does not influence inclusion formation in rodent and Drosophila models of PD Initial studies aimed at investigating phosphoryla tion at S129 were carried out in Drosophila, a model in which a-syn expression induces a loss of dopaminergic neurons or retinal degeneration, depending on the promoter used (Feany and Bender, 2000) . The co-expression of the Droso phila homologue of the kinase GRK2 with a-syn did not prompt or prevent the appearance of pro teinase K-resistant inclusions (Chen and Feany, 2005) , but it did enhance the formation of a-syn oligomers (Chen et al., 2009) compared to situa tions where only a-syn was over-expressed. These results suggest that increasing S129 phosphoryla tion does not promote a-syn fibrillization in vivo and argue in favour of the hypothesis that S129 phosphorylation results in the kinetic stabilization and/or accumulation of toxic a-syn oligomers. What remains unclear is whether the overexpression of GRK2 contributes to a-syn toxicity via mechanisms that are independent of a-syn phosphorylation. Further, the efficiency with which GRK2 phosphorylates a-syn and the turn over of S129-P was not investigated in these studies.
To overcome the drawbacks associated with kinase over-expression, a complementary approach was used, based on the expression of the S129D or S129A variant. In Drosophila, over-expression of the phosphomimic variant (S129D) yielded results that are comparable to those obtained with GRK2 over-expression: (1) inclusion formation by S129D was similar to that observed for the WT protein and (2) S129D formed more oligomeric forms of a-syn than the WT protein. Similarly, in vitro studies using recombinant proteins demonstrated that fibril for mation by the phosphomimics S129D/S129E is similar to that of the WT protein.
Together, these studies demonstrate that S ! D mutation at S129 alters the oligomerization, but not fibrillization, of a-syn.
Substitution of serine 129 with alanine (S129A) promotes a-syn inclusion formation and fibrillization in vivo and in vitro, respectively Interestingly, in both the fly and the rodent models, the S129A mutants forms five times more insoluble, proteinase K-resistant inclusions (but fewer oligomers) than WT and S129D a-syn (Chen and Feany, 2005; Chen et al., 2009) . In vitro, the S129A mutant forms fibrils more readily and to a greater extent than WT or the S129D mutant. Neither the S ! A nor the S ! E mutation alters the structure or morphology of a-syn fibrils in vitro. Initially, these findings appear to support the toxic hypothesis model, where accelerated fibrillization by this mutant ensures depletion of the toxic oligomers, thus explaining the reduced toxicity observed for S129A in the fly model. However, this correla tion between accelerated fibrillization and reduced toxicity did not hold consistently in various rodent models.
In rodent models, the effects of S ! D and S ! A substitutions on a-syn aggregation are variable
In rodent, over-expression of S129D and S129A a-syn, using AAV-mediated gene transfer in the substantia nigra, led to inconsistent observations, partially due to the different approaches used to characterize and quantify a-syn aggregation. At first, Gorbatyuk et al. (2008) reported that both S129D and S129A form punctate a-syn aggregates in vivo. The authors described a-syn S129D immu nostaining in neuronal cytoplasm as heterogeneous, whereas WT or a-syn S129A immunolabelling was more evenly distributed throughout the cell, with out providing quantitative evaluation of the level of aggregation. Furthermore, neither the biochemical and structural properties of these aggregates nor the a-syn oligomerization in this model was thor oughly investigated, which precludes comparison of the extent and type of a-syn aggregation in other models. On the contrary, a detailed study by Azer edo da Silveira et al. (2009) provided experimental observations of aggregation that agreed with data obtained in Drosophila: a-syn S129A forms more b-sheet-rich (thioflavin S-positive), proteinase K-resistant aggregates than WT and S129D a-syn. Finally, a recent study (McFarland et al., 2009 ) described a-syn-positive deposits in dopaminergic neurons, but revealed similar aggregation patterns for all three proteins (WT, S129D and S129A a-syn). The discrepancy with the previous two models might be due to the fact that McFarland et al. (2009) used a bi-cistronic mRNA to co express a-syn and green fluorescent protein (GFP), which may lead to lower expression of a syn compared to classical monocistronic RNA. Recent reports suggest neuronal toxicity associated with AAV-mediated over-expression of GFP in the substantia nigra, which could mask the differences in terms of neuronal loss caused by a-syn and the two S129 mutants (Baens et al., 2006; Sawada et al., 2010; Ulusoy et al., 2009 ). An additional contribut ing factor might be the fact the immunohistological analysis was carried out 6 weeks after virus injec tion, compared to 8 weeks in the studies by Azeredo da Silveira et al. (2009) and Gorbatyuk et al. (2008) .
Does phosphorylation enhance or protect against a-syn toxicity?
The accumulation of S129-P a-syn has been asso ciated repeatedly with disease states both in post mortem human brains and in various models of synucleinopathy (Lo Bianco et al., 2002; Neumann et al., 2002) . However, the extent to which does S129 phosphorylation and/or the accumulation of a-syn S129-P represent toxic events in the pathogenesis of PD is not yet fully understood. In Drosophila, the co-expression of a-syn with the GRK2 homologue, as well as over-expression of a-syn S129D, accelerates neu ronal loss compared with WT a-syn or S129A alone (Chen and Feany, 2005) , suggesting a toxic effect of a-syn S129-P. On the contrary, in a screening performed in yeast, aimed at identifying modulators of a-syn-induced toxicity, PLK2, which was recently shown to be an efficient kinase and a major contributor to S129 phosphorylation in vitro and in vivo, was shown to be protective (Mbefo et al., 2010) . This finding was confirmed in two other models, Caenorhabditis elegans and pri mary cultures of rat mesencephalic neurons (Gitler et al., 2009) . Studies from two independent groups based on the over-expression of the a-syn variants S129D and S129A in rat models support the hypothesis that a-syn S129-P is protective (Azeredo da Silveira et al., 2009; Gorbatyuk et al., 2008) . Indeed, over-expression of a-syn S129A in rat substantia nigra was reported to be more toxic than when the WT protein or S129D mutants were over-expressed (Azeredo da Silveira et al., 2009; Gorbatyuk et al., 2008) . The results from the two rat models support the hypothesis that phosphorylation of a-syn is pro tective. The following findings are consistent with this hypothesis: (1) PLK2 over-expression protects against a-syn-induced toxicity in yeast, C. elegans and primary rat neurons (Gitler et al., 2009) and 123 (2) disease-associated a-syn mutations (E46K and A30P) reduce the level of a-syn phosphorylation at S129 in cell culture and upon in vitro phosphor ylation with CK1 and PLK2 (Paleologou and Lashuel, unpublished data) . However, a recent study by Hyman and colleagues reported a similar toxicity for the three variants (WT, S129D and S129A) (McFarland et al., 2009 ). As mentioned above, the results from this study might be biased by co-expression of GFP and a-syn (Baens et al., 2006; Sawada et al., 2010; Ulusoy et al., 2009 ).
Different mechanisms may be involved in modulating a-syn toxicity in the Drosophila and rodent models of PD Although the increased aggregation of S129A cor relates well with its enhanced toxicity in the rat model (Azeredo da Silveira et al., 2009), the oppo site was observed in the fly model, where the increased aggregation of S129A, relative to WT and S129D, correlates with protection against a-syn-induced toxicity (Chen and Feany, 2005 ) (see Table 2 ). These observations clearly indicate the involvement of different neuropathologic mechanisms between the two models and suggest that a direct correlation between aggregation and toxicity in the fly and rat models may not be possi ble, especially if different approaches are used to assess and quantify toxicity and aggregation in the different models. Furthermore, there is no evidence that the aggregation pattern and structure of the aggregates/inclusions formed in the two models are identical. Initial studies by Chen and Feany reported the absence of thioflavin S staining or proteinase K-resistant aggregates in conditions of neuronal loss, where the accumulation of such aggregates occurs and correlates with neuronal loss in the rat model. Furthermore, in the rat model, S129D, which tends to be neuroprotective, formed fewer but larger aggregates than a-syn S129A (Azeredo da Silveira et al., 2009 ). More recently, Feany and colleagues showed, by western blot, that a-syn-associated toxicity correlates with the accumulation of soluble high molecular weight oligomeric a-syn species. Therefore, a careful ana lysis of data obtained in Drosophila suggests that large aggregates are well handled and do not impair cell survival, while soluble oligomers could be the primary toxic species in flies. Unfortunately, similar biochemical studies have not been carried out in the rat model, so direct comparison of the degree of oligomer formation and accumulation between the two models is not possible. An alternative hypoth esis, which could account for the differential toxicity of inclusions between rat and fruit flies, relies on the fact that Drosophila is naturally devoid of a-syn, whereas a rat homologue does exist and bears strong sequence similarity to the human a-syn (>95%). Previous studies have shown that mouse and rat a-syn form fibrils more readily than human a-syn and influence the oligomerization and fibril logenesis of human a-syn. Whether the interactions between rat and human a-syn could explain the differences in toxicity between the rat and the fly models remains unknown. However, this hypoth esis can be tested by over-expressing a-syn, S129D or S129A in the substantia nigra of one of the a-syn knockout mouse models.
Despite the differences, some consistent observations emerged from both models
The effect of phosphorylation using the phosphomimicking approach has yielded different results depending on the host organism (fly vs. rat) and the methods employed to assess and/or quantify aggregation and toxicity (see Table 2 ). Despite the discrepancy in terms of a-syn toxicity in the different models, comparing the results obtained in the Drosophila and rat models reveal some con sistent observations. (1) In addition to blocking phosphorylation, substitution of serine with alanine enhances the aggregation of a-syn in both animal models and in vitro, based on quantitative analysis of a-syn solubility and thioflavin S labelling. (2) In both fly and rat models, S129D exhibits similar aggre gation properties as the WT protein (Azeredo da Silveira et al., 2009; Chen and Feany, 2005) . Interestingly, both observations are in complete agreement with in vitro biophysical studies using purified recombinant a-syn. These studies showed that a-syn S129A aggregates more rapidly than the WT protein (Paleologou et al., 2008) . Although the effects of these two muta tions (S ! A and S ! D) on a-syn aggregation are reproducible in these different models (Table 1) , subsequent studies raised some con cern about their utility to model the phosphory lation state of the protein in vivo. A direct comparison of the structural and aggregation properties of monomeric S129D and S129-P, which was prepared by phosphorylating a-syn with CK1 or PLK2, demonstrated that phosphor ylation at S129 increases the conformational flex ibility of a-syn and strongly inhibits its fibrillization, whereas monomeric S129D exhibits structural and aggregation properties similar to those of the WT protein (Fig. 4c) . Observations of intraneuronal deposits are often a good start ing point for assessing aggregation, but further analyses to characterize the solubility of struc tural properties (using electron microscopy, thioflavin S staining and proteinase K digestion) and oligomerization state (immunoblotting using denaturing and native gel electrophoresis) of a syn within these inclusions are crucial to deter mine accurately how phosphorylation affects a syn aggregation and to elucidate the relationship between a-syn aggregation and toxicity in vivo.
What are the molecular mechanisms underlying phosphorylation-dependent a-syn toxicity?
A limited number of studies have attempted to dissect the cellular mechanism associated with phosphorylation-dependent a-syn neurotoxicity in vivo. Using electron microscopy, Azeredo da Silveira et al. (2009) sought to examine subcellu lar abnormalities induced by enhancing or block ing a-syn phosphorylation. These studies revealed the presence of lysosomal bodies and phagosome-like structures trapped within the aggregates, suggesting an attempt by the neurons to degrade the inclusions by macroautophagy (Azeredo da Silveira et al., 2009 ). In addition, they reported the association of a-syn S129A with membranous structures, endoplasmic reticu lum (ER) and Golgi apparatus, mostly in the vicinity of aggregates; these observations sug gested an impairment of ER-Golgi trafficking by non-phosphorylated a-syn. On the contrary, in SH-SY5Y cells, over-expression of a-syn S129A or inhibition of CKII decreases the activa tion of ER stress and caspase 3 cleavage. This study also reported that the increase of S129-P a-syn levels, following rotenone treatment, is associated with activation of these pathways (Sugeno et al., 2008) . Therefore, whether ER stress is due to a-syn or related to its phosphor ylation state remains to be determined. Azeredo da Silveira et al. (2009) suggested that Golgi-ER impairment results from a dysfunction of the The hydrodynamic radius of a-syn and a-syn S129D in a phosphate buffer is similar, around 28A (black bar), while the radius increased to 35A after phosphorylation of a-syn either at both S87 and S129 (p-WT) or at S129 only (pS87A) (dashed bars). In all cases, the radii rose to 36A in the presence of urea (white bars) corresponding to a true random-coiled state. (c) Illustration of the conformations populated by a-syn, a-syn S129E and a-syn S129-P (S129-p, S87-p) and of the long-range interactions involved (from Paleologou et al., 2008) .
microtubule-mediated transport system, as indi cated by the disarrayed neurofilament network when a-syn S129A is over-expressed. In cell lines, phosphorylation at S129 induces microtu bule retraction (Kragh et al., 2009 ). Phosphory lated a-syn (S129-P) also co-localizes with activated caspase 9 in different models of synu cleinopathy (Fournier et al., 2009; Yamada et al., 2004) . It is worth notifying that activated caspase 9 immunostaining is preferentially found in cells positive for S129-P, although this later category of cells represented only a minor subpopulation among neurons accumulating a-syn (Fournier et al., 2009 ).Over-expression of a-syn S129A or a-syn S129D in rat substantia nigra leads to acti vation of caspase 9 (Azeredo da Silveira et al.,
2009), indicating that caspase activation occurs independent of S129 phosphorylation and is likely to be a consequence of a-syn expression.
Novel phosphorylation sites
Recent studies from the Feany's laboratory and our group demonstrated that a-syn in vivo is phosphory lated at S87 and Y125. Studies by both groups sug gest that modifications at this site correlate with disease and significantly influence the oligomeriza tion and fibrillization of a-syn. The levels of S87-P were increased in brains of TG models of synuclei nopathies and human brains from AD, Lewy body disease (LBD) and MSA patients. Using antibodies 126 against phosphorylated a-syn (S129-P and S87-P), significant levels of immunoreactivity were detected in the membrane in the LBD, MSA and AD cases but not in normal controls. Given that the remaining potential phosphorylation sites in a-syn are highly conserved, it would not be surprising that these residues also undergo phosphorylation and may play a role in modulating the physiologic and/or pathogenic properties of a-syn. Therefore, further studies, using phospho-specific antibodies targeting the different potential phosphorylation sites, are necessary to map all the phosphorylation sites in a syn and elucidate their role in regulating its struc ture, aggregation and function(s).
Truncations
Truncated a-syn species are present in the normal brain and aggregate with the full-length a-syn in PD and related disorders
Biochemical characterization of aggregated a-syn from LBs revealed that it comprises predominantly full-length a-syn, in addition to small amounts of various truncated species with apparent molecular masses of 10-15 kDa (Anderson et al., 2006; Baba et al., 1998; Campbell et al., 2001; Crowther et al., 1998; Li et al., 2005; Liu et al., 2005; Okochi et al., 2000; Spillantini et al., 1998) . At least five species were detected using mass spectrometry and repre sent C-terminal truncations ( Fig. 5) (Anderson et al., 2006) . A comparison between LB-derived and cytosolic a-syn forms showed that some trun cated species were exclusively observed in the a syn derived from LB. The cleavage sites were deter mined by tryptic digestion and sequencing using liquid chromatography followed by mass spectro metry (LC-MS/MS). Species terminating at D-115 (a-syn-D115), D-119 (a-syn-D119), N-122 (a-syn N122), Y-133 (a-syn-Y133) and D135 (a-syn D135) were identified ( Fig. 5) (Anderson et al., 2006) . Three additional truncated forms of a-syn were also identified in samples from PD, DLB and MSA brain tissues: two C-terminal truncated forms
(ending approximately between amino acid resi dues 102-125 and 83-110, respectively) and a third N-and C-terminal truncated isoform, which were only detectable in aggregated forms of a-syn (Li et al., 2005; Liu et al., 2005; Tofaris et al., 2003) . Interestingly, these isoforms are present in healthy and diseased brains, suggesting that a-syn trunca tion occurs under physiologic conditions. The most striking difference is that PD and DLB extracts contained appreciable amounts of truncated a-syn in SDS-and urea-soluble fractions and a significant level of the N-and C-terminal truncated forms (Li et al., 2005; Liu et al., 2005) . All together, these observations show that a-syn truncation occurs under normal conditions and suggest that the trun cated a-syn may have a normal physiologic role. These findings also suggest that the C-terminal trun cated forms that accumulate selectively in LBs or insoluble fractions aggregate more readily and could act as effective seeds to accelerate the aggregation of the full-length protein.
C-terminal truncations promote the fibrillization of a-syn in vitro
Among the various post-translational modifications identified to date, the C-terminal deletion variants of a-syn consistently exhibit higher fibrillization pro pensity relative to the WT full-length protein. These findings, combined with the observation obtained for C-terminal deletion variants of a-syn in human brains and brains of TG animal models of PD (Li et al., 2005) , led to the hypothesis that proteolytic processing of the C-terminus could be responsible for the initiation of a-syn fibrillogenesis in PD, pos sibly via a seeding mechanism. Lee and colleagues also reported several naturally occurring C-terminal deletion variants (including amino acids 1-119 or 1-122) in a-syn over-expressing TG mice and pro posed that proteolytic processing of the C-terminus of a-syn may play a critical role in the initiation of a-syn aggregation and fibrillogenesis in vivo. using recombinant proteins and by over-expres sing C-terminal deletion variants in cell lines.
In vitro fibrillization studies have consistently shown that truncation of various segments of the C-terminal residues 110-140 enhances the rate of a-syn aggregation and fibrillogenesis. Some fragments (1-110; 1-120) promote nucleation and seed the aggregation of full-length a-syn (Li et al., 2005; Murray et al., 2003) . Serpell et al. (2000) reported that 1-87 a syn aggregates more rapidly than 1-120 a-syn and rat a-syn, which aggregates faster than human a syn (Rochet et al., 2000) . Similarly, studies by Murray et al. (2003) showed that the C-terminal 128 truncated a-syn variants 1-89, 1-102, 1-110, 1-120 and 1-30 aggregated more rapidly than the fulllength protein with the 1-110 variant showing the most robust enhancement of a-syn fibril forma tion. Interestingly, the 1-102 and 1-110 variants, but not 1-120, seed the fibrillization of the fulllength protein in vitro. Together, the results from these studies combined with data from solid-state NMR (Bertini et al., 2007; Wu et al., 2008) , and immunogold labelling of a-syn fibrils (Murray et al., 2003) suggest that fibril formation by a-syn is mediated by its N-terminal domain (~1-90), whereas the C-terminal region remains flexible and may play a role in inhibiting the aggregation of monomeric a-syn (Murray et al., 2003) . Subse quent NMR studies provided further evidence in support of this hypothesis and demonstrated that the C-terminal domain participates in long-range interactions with the N-terminal region of a-syn. These interactions shield the hydrophobic regions within the protein and prevents its self-assembly (Bertoncini et al., 2005; Pawar et al., 2005) . Sev eral groups have also shown that the C-terminal 20-30 amino acids, which are highly anionic, inhi bit fibrillization Kim et al., 2002; Tofaris et al., 2006) . This inhibition is mediated by transient interactions between the C-terminal region and the amyloidogenic NAC region. Truncations of residues in this region or a charge-neutralizing effect (e.g. by divalent metals such as Ca 2þ and Cu 2þ and polyamines) may account for the fibril acceleration by cations, including polyamines and C-terminal deletion mutants of a-syn (Antony et al., 2003; Cohlberg et al., 2002; Goers et al., 2003) and certain metals (Paik et al., 1999; Uversky et al., 2001; Yamin et al., 2003) .
Several enzymes have been implicated in the proteolysis of a-syn
Although the inhibitory activity of the C-terminal sequence suggests that proteolytic cleavage of this region could promote the fibrillization of a-syn in vivo, a protease that selectively cleaves this sequence has not been identified. A number of enzymes have been implicated in a-syn cleavage and generation of truncated fragments. Neurosin, a trypsin-like serine protease, was detected in LBs (Iwata et al., 2003; Ogawa et al., 2000) . The in vitro cleavage of a-syn by neurosin generates one major fragment 1-80, which does not aggre gate in vitro (Iwata et al., 2003) and three minor ones: 1-97, 1-114 and 1-121 (Kasai et al., 2008) (Fig. 5) . Interestingly, the phosphorylated form (S129-P) and the disease-associated mutants (A30P and A53T) are more resistant to proteoly sis by neurosin (Kasai et al., 2008) .
The intracellular calcium-dependent protease calpain cleaves monomeric WT or mutant (A30P and A53T) a-syn at several sites within the NAC region to yield fragments that inhibit the aggrega tion of the full-length protein (Mishizen-Eberz et al., 2003 (Fig. 5) . The major generated fragments consist of two N-terminally truncated fragments, 58-140 and 84-140, and four C-termin ally truncated forms, 1-57, 1-73, 1-75 and 1-83 (Mishizen-Eberz et al., 2003) . Furthermore, using N-terminal sequencing and an antibody against the N-terminal truncated a-syn, Dufty et al. (2007) reported another calpain cleavage site between the residues 9 and 10. In the fibrillar state, calpain-mediated cleavage occurs exclu sively within the C-terminal region (residues 114 and 122) (Mishizen-Eberz et al., 2005) , probably due to this region remaining flexible and exposed to proteases. Calpain-cleaved a-syn species were found in LB and Lewy neurites in diseased brain and co-localize with activated calpain, suggesting a link between a-syn proteolysis by this enzyme and a-syn aggregation and pathology (Dufty et al., 2007) .
Recently, a lysosomal enzyme, cathepsin D was reported to generate two forms of C-terminally truncated a-syn detectable at 12 and 10 kDa, respectively (Sevlever et al., 2008; Takahashi et al., 2007) . Using antibodies to different a-syn epitopes, the authors demonstrated that these fragments end approximately between the residues 91-98 and 91-115, respectively (Sevlever et al., 2008; Takahashi et al., 2007) . Sevlever et al. (2008) also demonstrated that cathepsin-gener ated a-syn fragments are the major component of oligomeric a-syn species formed under oxida tive stress. The formation of these correlated with an increase of CKII expression and a-syn phos phorylation in cell culture. These observations suggest a possible relationship among a-syn trun cation, phosphorylation and oligomerization when cells are exposed to oxidative stress.
Although ubiquitin-mediated degradation of a syn has been proposed by several studies, a-syn was reported to undergo proteolytic cleavage by the proteasome, in the absence of ubiquitination (Tofaris et al., 2001) . The caspase-like activity of the 20S proteasome generates four a-syn frag ments corresponding to 1-73, 1-83, 1-110 and 1-119 (Lewis et al., 2010; Liu et al., 2005) . In vitro aggregation assay showed that the 1-110 and 1-120 a-syn fragments aggregate more rapidly than the full-length and can seed the aggregation and formation of hybrid protofibrils of truncated and non-truncated a-syn (Lewis et al., 2010; Liu et al., 2005) . The PD-linked mutations do not significantly affect the cleavage of a-syn by the proteasome (Lewis et al., 2010) ; however, the fragments containing the mutation A53T aggre gated more rapidly than the truncated WT and full-length A53T and were shown to seed and accelerate the aggregation of the full-length pro tein (Liu et al., 2005) .
The matrix metalloproteases (MMPs, e.g. MMP-1 and MMP-3), a family of zinc-dependent endopeptidases, also cleave a-syn and generate several C-terminally truncated fragments in vitro (1-54, 1-57, 1-79 and 1-78) (Levin et al., 2009; Sung et al., 2005) . Levin and collaborators showed that a-syn in vitro aggregation is increased after a limited proteolysis by MMPs. However, higher MMP concentrations resulted in an inhibition of a-syn aggregation (Levin et al., 2009 ), most likely due to increased MMP-mediated cleavage within the NAC region, which is essential for a-syn oli gomerization and fibril formation.
Truncation (in vivo studies)
To explore in vivo the effect of C-terminal trunca tions on the aggregation and toxicity of a-syn, TG flies and mice over-expressing various truncated forms of a-syn have been generated (see Table 2 ). In Drosophila, two different truncations have been investigated: a-syn 1-87, corresponding to a non natural truncation with the entire acidic C-terminal domain was deleted and a pathological truncation, a-syn 1-120, with the last C-terminal amino acids removed (Periquet et al., 2007) . The 1-87 a-syn variant did not aggregate or induce toxicity when expressed in Drosophila, although expression at levels similar to that of the WT a-syn could not be reached, which may account for these observations. Conversely, the pan neuronal expression of a-syn 1-120 resulted in the appearance in the Drosophila brain, of more abundant oligomers and a-syn positive, proteinase K-resistant inclusions as com pared to the full-length protein expressed at similar levels. The formation of inclusions by a-syn 1-120 was accompanied by a loss of dopaminergic neu rons, which occurred slightly faster for the trun cated than for the full-length a-syn.
Three different TG mice have been produced, expressing truncated variants of a-syn under the control of the TH or nestin promoter. The first TG mice were generated in a strain devoid of endogenous a-syn; the expression level of a-syn 1-120 was lower than what is expected for the rodent protein (Tofaris et al., 2006) . Dopaminergic neurons from the olfactory bulbs and from the substantia nigra presented some a-syn-positive fibrillar inclusions (thioflavin S-positive). Despite the fact that expression of 1-120 resulted in the formation of both non-fibrillar and fibrillar a-syn aggregates, no neuronal loss was observed at 12 months of age, although DA and homovanilic acid (HVA) levels were decreased in 3-month-old animals. Wakamatsu et al. (2008) generated TG mice that over-express either the pathogenic mutant A53T or a truncated variant of this mutant in catecholaminergic neurons comprising residues 1-130 (a-syn A53T, 1-130). The expression of In various model over-expressing a-syn, the appearance of a-syn S129-P deposits correlates with the development of ubiquitin immunoreactivity, proteinase K-resistant and thioflavine S-positive inclusions. n.d.: no data; þ: present; -: absent; CBA: CMV beta-actin; CMV: cytomegalovirus; DA: dopamine; Dopac: 3,4-dihydroxyphenylacetic acid; e-microscopy: electron microscopy; GFP: green fluorescent protein; HVA: homovanilic acid; HMW: high molecular weight species; IHC: immunohistochemistry; KO: knockout; PK: proteinase K; TH: tyrosine hydroxylase positive; Thio S: thioflavine S staining; ubi: ubiquitin; WB: western blot.
exogenous a-syn ranged from 1.3-to 1.6-fold the level of the endogenous protein. When the A53T 1-130 variant was over-expressed, the animals dis played a developmental decrease in the number of dopaminergic neurons from the substantia nigra, while animals expressing the full-length a-syn A53 did not present any defect. No abnormal proteinac eous accumulations were detected in the affected brain regions, despite the fact that the absence of endogenous a-syn was expected to promote aggre gation (Wakamatsu et al., 2008) . Finally, Daher et al. (2009) described the consequences of Cre dependent expression of the C-terminal truncation a-syn 1-119. The authors did not observe any protein deposition by immunohistochemistry or neuronal loss, although dopamine, 3,4-dihydroxy phenylacetic acid and HVA were decreased in the striata of 10-month-old mice; the low protein level likely explains this mild phenotype, as the expres sion of a-syn 1-119 was 10-fold lower than that of the endogenous protein.
The toxicity of the C-terminal truncated forms of a-syn was also assessed using in vitro cell death assays. The addition of hybrid protofibrils, com prising truncated (1-110 or 1-120) and full-length a-syn, significantly increased a-syn-induced toxi city in SH-SY5Y neuroblastoma compared to the addition of monomeric truncated or full-length a syn separately (Li et al., 2005) . These data suggest that truncated a-syn may enhance cell death by promoting the formation of toxic protein aggre gates (Liu et al., 2005) . Co-over-expression of the C-terminal fragments (1-110 and 1-120) and the full-length protein also enhanced a-syn-induced cell death by increasing the cell vulnerability to oxidative stress (Li et al., 2005; Liu et al., 2005) .
The emerging results from the various studies discussed above demonstrate that C-terminal trun cated a-syn aggregates more than the full-length protein in Drosophila, but the results from TG mice are variable. Indeed, while Tofaris et al. (2006) reported the accumulation of fibril and nonfibrillar 1-120 a-syn inclusions, Wakamatsu et al. (2008) did not report the formation of any deposits of the A53T 1-130 variant, despite the fact that this mutant aggregates more than the full-length protein 132 in vitro. The discrepancies might be due to the lack of endogenous a-syn in the experiment by Tofaris et al. (2006) . In vitro studies suggest that the pre sence of endogenous a-syn is expected to interfere with the fibrillization of human a-syn in the rat and mouse models. Consistent with this hypothesis, fibrillar aggregates were observed in mouse and fly models that do not express human a-syn (Chen and Feany, 2005; Tofaris et al., 2006) . C-terminal trunca tions slightly increase neuronal loss compared to the normal a-syn in Drosophila, but not in two out of three TG mouse models. For comparison, pre viously published studies in mouse, targeting expres sion of full-length WT or PD-associated a-syn mutants (A30P & A53T) into dopaminergic neu rons with the TH-promoter, report no neuronal loss (Matsuoka et al., 2001) , or a age-associated neurodegeneration at 19 months in the cases of A30P and A53T (Richfield et al., 2002; Thiruchel vam et al., 2004) . Only expression of a-syn 1-130 provoked a strong phenotype, with impaired devel opment of neurons from the substantia nigra pars compacta. However this model does not reproduce the progressive cell loss or the associated neuro pathology characteristic of synucleinopathies.
Ubiquitination

Ubiquitin-positive inclusions are a neuropathologic hallmark of PD and related disorders
Several neuropathologic studies have shown that a large proportion of LBs present in the substantia nigra, the locus coeruleus, the hippocampus and the cortex of brain with PD and related disorders, are positive for a-syn (Baba et al., 1998; Spillantini et al., 1997 ) and ubiquitin (Gomez-Tortosa et al., 2000 Hasegawa et al., 2002; Kuzuhara et al., 1988; Lowe et al., 1988; Manetto et al., 1988; Sampathu et al., 2003; Tofaris et al., 2003) (Fig. 6 ). Double-immunostaining using anti-a-syn and anti-ubiquitin antibodies revealed that the core of LBs is immunoreactive for both proteins and is surrounded by a rim of a-syn (Gomez-Tortosa et al., 2000; Mezey et al., 1998) (Fig. 6c) . Other intra-cytoplasmic inclusions, larger than LB and without halo, called pale bodies, are positive for a-syn but only occasionally for ubiquitin (GomezTortosa et al., 2000; Tofaris et al., 2003) . a-Synu clein and ubiquitin co-staining is also frequent in Lewy neurites (e.g. in the hippocampus) (GomezTortosa et al., 2000) . Moreover, a-syn and ubiqui tin show extensive co-localization in the glial cyto plasmic inclusions in MSA.
Biochemical analysis of purified LBs and/or LBderived preparations, using western blotting and mass spectrometry techniques, confirmed that some of the a-syn within LBs is ubiquitinated (Anderson et al., 2006; Hasegawa et al., 2002; Sam pathu et al., 2003; Tofaris et al., 2003) . Interest ingly, the majority of a-syn species found in LB are mono-or di-ubiquitinated. Some tri-ubiquiti nated a-syn species have been detected by western blots, but no polyubiquitin chains were detected on a-syn isolated from LB or other brain tissues (Anderson et al., 2006; Hasegawa et al., 2002; Nonaka et al., 2005; Sampathu et al., 2003) . These find ings suggest that ubiquitination of a-syn may be involved in regulating some of its pathophysiologic properties and imply that ubiquitin-mediated degradation is not likely to be the major physiolo gical mechanism for degrading a-syn. Consistent with this hypothesis, Tofaris et al. (2001) demon strated that non-ubiqutinated a-syn can be degraded by the proteasome. Furthermore, studies from several groups have implicated other protein clearance pathways in the degradation and turn over of a-syn, including lysosomal and autophagic pathways (Cuervo et al., 2004; Vogiatzi et al., 2008; Webb et al., 2003; Xilouri et al., 2008) . In vitro fibrils In vitro monomers + Cell culture 133 1 Fig. 6 . Ubiquitin, a hallmark of LB, covalently modifies a-syn. Ubiquitin immunostaining in a nigral (a) and a cortical (b) LB (arrow) from synucleopathies diseased brains. (adapted from Chu et al., 2000) . (c) Co-immunofluorescent labelling of a-syn and ubiquitin showing their co-localization in a LB from the substantia nigra of a PD patient: the staining shows ubiquitin and a-syn in the core of this inclusion and the a-syn alone in the periphery. Scale bar = 10 mm (adpated from Mezey et al., 1998) . (d) Schematic representation of a-syn showing the lysine which can be ubiquitynated and the major sites of ubiquitination identified in LB (upper part; Anderson et al., 2006) or in cell culture and in vitro studies (lower part; Nonaka et al., 2005 , Rott et al., 2008 . 134 carboxy-terminal hydrolase L1 (UCH-L1) and seven in absentia homologue (SIAH) (Lee et al., 2008; Liani et al., 2004; Rott et al., 2008) . Interest ingly, the genes coding for Parkin and UCH-L1 are linked to familial forms of PD and to PD suscept ibility, respectively (Liu et al., 2002; Shimura et al., 2000) . Both Parkin and SIAH have been detected in LBs in PD brains (Bandopadhyay et al., 2005; Liani et al., 2004) Ubiquitination sites Ubiquitination of a-syn occurs at multiple lysine residues and the sites of ubiqutination depend on the conformational and/or aggregation state of the protein. There are 15 lysine (K) residues in a-syn, the majority of which are distributed within the N-terminal repeat sequences. The remaining resi dues are K80, K96, K97 and K103 (Fig. 6) . Using single-site mutagenesis of lysine residues (K ! R) and enzyme (lysyl endopeptidase AP1) digestion followed by peptide mapping using mass spectro metry, different groups have identified the possi ble lysine residues in a-syn that undergo ubiquitination in vitro and in vivo. In vitro ubiqui tination of recombinant a-syn revealed that the monomeric and fibrillar forms of a-syn undergo ubiquitination at distinct lysine residues. In vitro, monomeric a-syn undergoes ubiqutination at sev eral lysine residues including K10, K21, K23, K32, K34, K43 and K96, with the major ubiquitin-con jugated sites represented by K21, K23, K32 and K34 (Nonaka et al., 2005; Rott et al., 2008) . Muta tion of these residues to argnine (R) results in a >90% reduction of ubiquitinated a-syn (Nonaka et al., 2005) . Similar results were obtained when these mutants were expressed in cell lines. Ubiqui tination of recombinant a-syn using rabbit reticu locytes fraction II or rat brain extracts revealed similar ubiquitination patterns with K21 and K23 being the major ubiquitination sites (Nonaka et al., 2005) . Interestingly, ubiquitination of a-syn fibrils prepared from recombinant a-syn, under identical conditions, occurs predominantly at K6, K10 and K12 (Nonaka et al., 2005) . This observation may be explained by the fact that in a-syn fibrils, the N-terminal region remains acces sible for interaction with ubiquitin-protein ligases. The ubiquitination sites linked to PD and related disorders have been identified form LB-purified a-syn. Using trypsin digestion followed by LC MS/MS analysis, Anderson et al. (2006) identified residues K12, K21 and K23 as a major sites of ubiquitination in a-syn.
Does ubiquitination of a-syn enhance or prevent its aggregation and toxicity?
While the role of ubiquitination in modulating a syn aggregation in vivo remains poorly under stood, it is not essential for inclusion formation in vivo, as evidenced by the fact that not all a-syn inclusions in TG mouse models are ubiquitinated (Sampathu et al., 2003; van der Putten et al., 2000) . The role of ubiquitination in modulating a-syn aggregation and toxicity was addressed by investigating the in vitro ubiquitination of recom binant a-syn, in cell culture and TG animal model. In the animal models, attempts to modu late the level of a-syn ubiquitnation, and thereby attenuate a-syn-induced neurotoxicity, were based on the regulation of Parkin expression or the over-expression of ubiquitin. In Drosophila (Haywood and Staveley, 2004; Yang et al., 2003) , Parkin over-expression protects against a-syn induced toxicity without modifying a-syn levels. Recently, Lee and collaborators demonstrated that the over-expression of ubiquitin has no effect per se on overall adult retinal or dopami nergic neuronal structure or viability (Lee et al., 2009 ), but co-expression of ubiquitin and a-syn suppresses a-syn-induced motor impairment (negative geotactic locomotor response) and cell degeneration in Drosophila eyes and in the DM1 cluster of dopaminergic neurons. Furthermore, the authors demonstrated that expression of the K48R, and not K63R ubiquitin mutants, suppresses the protective effect of ubiquitin 135 (Lee et al., 2009) , suggesting that the ubiquitin mediated neuroprotective effect is potentially dependent on the K48 polyubiquitin linkage, a signature targeting proteins for proteasomal degradation (Lim et al., 2005) . Together, these data suggest that a-syn ubiquitination could pro tect against a-syn toxicity in Drosophila PD mod els, by targeting a-syn for proteasomal degradation and enhancing the function of the ubiquitin proteasome system. In a rat model, over-expressing Parkin protects against a-syn toxicity without affecting a-syn levels (Lo Bianco et al., 2002) . Unfortunately, none of the reported studies in fly and rat models characterized the amount of ubiquitinated a-syn or attempted to map the site of modification and/ or characterize the ubiquitination pattern of a-syn. In TG mice over-expressing a-syn, the knockout of the parkin gene does not modify a-syn quantity (Fournier et al., 2009; Stichel et al., 2007; von Coelln et al., 2006) or levels of ubiquitinated a syn (von Coelln et al., 2006) . However in one of these models, the levels of S129-P a-syn deposits that are ubiquitinated decreased in the absence of Parkin (Fournier et al., 2009) . But the same study showed, by in vitro ubiquitination, that neither a syn nor S129-P a-syn is a Parkin substrate, sug gesting that the fibrils rather than the monomeric protein might be ubiquitinated by Parkin. The decreased ubiquitination of S129-P a-syn inclu sions is associated with a delayed appearance of the neurodegenerative phenotype, indicating a possible toxicity of Parkin-mediated ubiquitina tion. On the one hand, this report agrees with data describing a lack of synergy between Parkin deficiency and a-syn over-expression (von Coelln et al., 2006) and the previously described protec tive effect of Parkin expression against a-syn induced toxicity (Haywood and Staveley, 2004; Lo Bianco et al., 2002; Petrucelli et al., 2002; Yang et al., 2003) . On the other hand, these results are in agreement with data showing that ubiquiti nation of a-syn by SIAH promotes the formation of cytotoxic inclusions (Rott et al., 2008) . To con clude, the limited studies reported in the literature indicate that Parkin does not modulate a-syn levels, but it might be involved in its deposition in vivo. Whether the ubiquitinated aggregates are toxic or protective is still controversial and requires further investigations.
In cell culture, endogenous SIAH co-localizes with a-syn and is, in part, responsible for its mono and di-ubiquitination in mammalian cell lines and human neuroblastoma, since the suppression of SIAH expression using shRNA completely abolishes a-syn ubiquitination (Lee et al., 2008; Rott et al., 2008) . Moreover, the co-expression of a-syn and SIAH enhances a-syn mono and di ubiquitination (Lee et al., 2008; Rott et al., 2008) . Co-expression of a-syn, an E3 ubiquitin protein ligase (Siah-1) and ubiquitin results in the formation of predominantly mono and di-ubi quitinated a-syn species (Lee et al., 2008) . Siah-1 or Siah-2-mediated ubiquitination enhances the aggregation of a-syn and formation of a-syn-posi tive inclusion in PC12 cells and SH-SY5Y human neuroblastoma (Lee et al., 2008; Rott et al., 2008) . In vitro ubiquitination of a-syn by SIAH promotes the formation of higher molecular weight a-syn aggregates as determined by western blot analysis (Rott et al., 2008) . This observation suggests that ubiquitination by SIAH may enhance a-syn aggre gation in vitro. These findings were confirmed by electron microscopy studies showing that SIAH ubiquitinated a-syn forms more aggregates than the non-ubiquitinated form (Rott et al., 2008) . Interstingly, the SIAH-ubiquitinated a-syn was reported to enhance the aggregation of non-ubi quitinated a-syn (Rott et al., 2008) , suggesting that ubiquitinated a-syn may promote aggregation by seeding the non-ubiquitinated forms. The impact of the phosphorylation and the disease-linked mutations on a-syn ubiquitination in vitro is minor (Nonaka et al., 2005; Rott et al., 2008) . A30P and 453T mutations reduce the ability of a-syn to bind to SIAH (Lee et al., 2008 ) but they do not disrupt the efficiency of the ubiquitination (Rott et al., 2008) .
The formation of ubiquitinated inclusions asso ciated with cell death after the inhibition of the 136 proteasome system in neuronal cell culture and in vivo has been reported by several groups (McNaught et al., 2002 (McNaught et al., , 2004 Rideout and Stefa nis, 2002) . Inhibition of the proteasome or impair ment of UCH-L1 activity induced neuronal degeneration and an increased intracellular expression of a-syn and ubiquitin (McNaught et al., 2002; Rideout and Stefanis, 2002) . After 12 h incubation with proteasome inhibitors, intracellular inclusions immunoreactive for a-syn, ubiquitin and the chaperone Hsp70 were detected in the apoptotic cells (McNaught et al., 2002; Rideout and Stefanis, 2002) . Interestingly, McNaught and collaborators highlighted the vul nerability of the dopaminergic versus the GABAergic neurons to proteasome inhibition (McNaught et al., 2002) , which they suggested could explain the specific degeneration of the nigral dopaminergic neurons in PD. Similar observations were reported in differentiated and undifferentiated PC12 neuroblastoma after the inhibition of the proteasome (Rideout et al., 2001) . Lactacystin-exposed cells showed diffuse ubiquitin immunoreactivity, and in some other cells, focal cytoplasmic accumulation of ubiquitin immunoreactivity was detected (Rideout et al., 2001) . It is noteworthy that not all the ubiquitin inclusions were positive for a-syn. This observa tion suggests that the accumulation of a-syn within the intracellular inclusion depends on the cell type. In a rat model, McNaught showed that the impairment of the proteasome by systemic expo sure to proteasome inhibitors induced the devel opment of progressive parkinsonism, neuronal degeneration in different brain regions including the substantia nigra and the formation of LB-like inclusions positive for a-syn and ubiquitin (McNaught et al., 2004) . Together, the data generated from the proteasome inhibition models show that the formation of the ubiquitin and a-syn-positive inclusions could be associated with neuronal toxicity in vivo and in vitro. However, whether the a-syn in these inclusions is ubiquiti nated and which residues are implicated remain to be elucidated.
Conclusions
Significant advances have been made towards the identification of post-translational modifications of a-syn (Fig. 7) . To date, several post-translational modifications have been identified, some of which appear to be strongly linked to the pathology in PD and related synucleinopathies (e.g. phosphor ylation). Although the results from the studies discussed above demonstrate that introducing these modifications into a-syn or mutating the site of modification influences the structure and/ or aggregation properties of the protein, reconcil ing the effects of these modifications in the dif ferent model systems is complicated by several factors: (1) different mechanisms of toxicity may be involved in modulating a-syn aggregation and toxicity in different model organisms (e.g. Droso phila vs. rodents); (2) differences in the methods used to assess aggregation and toxicity and lack of standardized rigorous approaches for the ana lysis of soluble and aggregated forms of a-syn, particularly in cellular and animal models, which have made it difficult to make direct comparisons between the various studies; (3) mutations that are generally used to mimic post-translational modifications do not truly reproduce all aspect of these modifications (e.g. use of phosphomi mics; see below); (4) the majority of the in vivo studies focused primary on the effect of modifica tions on a-syn aggregation and toxicity (Table 2) and very little on elucidating the molecular mechanisms and cellular pathways altered by these modifications and (5) the cross-talk between different modifications is currently diffi cult to reproduce and study in vitro or in vivo. Recent studies suggest that a-syn is phosphory lated at multiple sites, and phosphorylation at tyrosine residues modulates a-syn aggregation and toxicity induced by S129-P, highlighting the importance of investigating the interplay between the different post-translational modifications. These challenges, combined with the lack of good cellular and animal models that reproduce the pathology and neuronal loss in humans, have limited our ability to translate the knowledge gained from the identification of these modifica tions to an improved understanding of the molecular mechanisms underlying a-syn toxicity and developing new therapies for PD and related disorders. Therefore, several key outstanding questions concerning the role of post-transla tional modifications in PD remain unanswered (see Box 1).
Looking beyond aggregation
The majority of a-syn modifications were initially identified and implicated in disease pathogenesis solely on the basis of isolation and/or co-localiza tion of modified a-syn within LBs or inclusions from diseased brains or TG animal models. There fore, studies on these modifications have focused primarily on their role in modulating a-syn aggre gation and toxicity rather than their effect on the functional and physiologic properties of the pro tein, including its stability, subcellular localization, membrane interactions and clearance mechanisms (Fig. 7) . Post-translational modifications of pro teins represent important molecular switches for regulating protein-protein and protein-ligand interactions and thus protein function in health and disease. The C-terminal region of a-syn has been implicated in the majority of a-syn interac tions with proteins (Fernandez et al., 2004; Gias son et al., 2003; Jensen et al., 1999) and metal ions (Brown, 2007; Paik et al., 1999) . Therefore, trun cation and/or phosphorylation at single or multi ple sites is likely to influence a-syn affinity to proteins, metals and other ligands (e.g. dopamine and polyamines) and alter the biochemical and biological processes regulated by its interaction with these molecules. For example, a-syn interacts with the microtubule-associated protein tau and stimulates tau phosphorylation (Jensen et al., 1999) and fibrillogenesis (Frasier et al., 2005) both in vitro and in vivo. The tau binding site was mapped to the C-terminal region (AA 87-140) of a-syn. Phosphorylation at S129, but not Y125, was also reported to reduce the rate of Box 1
1. What percentage of a-syn is modified in vivo and is there a correlation between the level of modified a-syn and disease progression? With the exception of phosphorylation of a-syn at S129, quantitative assessments of the levels of modified a-syn in the soluble and aggregated states of the proteins, relative to total a-syn, are lacking. Studies by Iwatsubo and colleagues suggest that >90% of a-syn within LBs is phosphorylated at S129.
2. Do these modifications occur before and/or after a-syn aggregation and LB formation? For all reported modifications, it remains unclear whether the presence of modified a-syn in LB and other inclusions reflects their active role in the initiation of a-syn aggregation and development of pathology or a cellular response aimed at clearing unmodified forms of a-syn within LB. Interestingly, all disease-associated modifications, with the exception of phosphorylation at S87, occur at flexible regions that remain accessible in the monomeric, oligomeric and fibrillar states of a-syn. Recent findings that phosphorylation of a-syn at serines (S87 and S129) and tyrosines (Y125, Y133 and Y136), covalent cross-linking by tissue transglutaminase and nitration all inhibit a-syn fibril formation in vitro support the notion of these post-translational modifications being a late event rather than a prerequisite for a-syn aggregation.
3. What is the effect of each modification on the structure of monomeric a-syn and its binding to membranes, oligomerization and fibrillogenesis? The answer to this question lies in our ability to introduce site-specific modifications in a-syn and produce the desired protein in sufficient quantities to perform structural and biophysical studies. These site-specific modifications may not be possible at this stage in vivo but are achievable at the protein and single-cell level. Recent advances in chemistry have made it possible to introduce site specifically single or multiple post translational modifications into proteins. A detailed structural understanding of how these modifications alter the structural properties and dynamics of monomeric a-syn will provide important insight into their role in triggering or inhibiting a-syn aggregation and/or interactions with other proteins and cellular compartments.
4.
What is the effect of each modification on the stability, degradation and functional properties of a-syn? Only an integrative interdisciplinary approach with standardized methods and measures for assessing changes in a-syn properties would bring us closer to addressing the key outstanding mechanistic questions on the role of a-syn post-translational modifications in PD and translate this knowledge into novel therapies.
5. Is there cross-talk between the different post-translational modifications in a-syn? Thus far, all the modifications of a-syn have been investigated separately, and studies aimed at elucidating the interdependence and relationship between the different modifications are lacking. Different forms of a-syn are modified at multiple sites. Phosphorylation at Y125, ubiquitination or C-terminal truncations co-exist with S129-P, although the sequence of modification remains unknown. More importantly, the residues involved in these modifications are in close proximity to each other and result in a dramatic change in the structure and aggregation of monomeric a-syn. Therefore, it is clear that modifications at these residues will likely have a dramatic effect on a-syn interactions with other enzymes and susceptibility to modifications by these enzymes. 6. What are the natural enzymes involved in regulating each of these modification? Selective and efficient site-specific modification of a-syn at single or multiple sites in vivo are currently not possible because the identity of the natural enzymes (e.g. kinases, phosphatases, E3 ubiquitin ligases, hydrolyases and proteases) responsible for regulating the dynamics of these modifications remain unknown. The existing tools and methods (e.g. the use of phosphomimics or expression of truncated a-syn variants) do not allow for investigating the effect of post-translational modification with spatial and temporal resolution. Several candidate enzymes have been implicated in the phosphorylation and proteolysis of a-syn and are currently being tested and validated as potential therapeutic targets. The identification and validation of enzymes that regulate specific a-syn post-translational modifications will provide more effective means for modulating the level of these modifications and determining their role in disease pathogenesis in vivo, using genetic manipulations and/or small molecule inhibitors of these enzymes. Furthermore, this knowledge will allow us to identify the cellular pathways regulating these modifications, which may yield more effective therapeutic targets.
7. Can we prevent a-syn aggregation and toxicity in vivo by modulating the type and extent of post translational modification at specific residue(s)? To be able to answer this question, we must use approaches and tools that allow site-specific modulation of post-translational modifications in vivo.
Although the identification of candidate enzymes involved in regulating these modifications represents a first important step, it is crucial to demonstrate that the effect of modulating the activity of these enzymes is mediated specifically by a-syn, more effective means for modulating the level of these modifications and determining their role in disease pathogenesis in vivo using genetic manipulations and/or small molecule inhibitors of these enzymes. Furthermore, this knowledge will allow us to elucidate the cellular pathways in regulating these modifications, which may yield more tractable therapeutic targets and pathways.
a-syn transport (Saha et al., 2004) . Together, these findings suggest that reversible phosphoryla tion or truncations within the C-terminal region (Y125 or S129) may be involved in regulating the association/dissociation with tau and other neuro nal proteins (e.g. tau, synphilin (Lee et al., 2004) , phospholipase D (PLD) (Payton et al., 2004; Pro nin et al., 2000 ), 14-3-3 (Ostrerova et al., 1999 , metals (Liu et al., 2005) and lipids. Phosphoryla tion within the C-terminal region (S129 or Y125) or the incorporation of phosphorylation mimick ing mutations at these residues also reportedly reduces membrane binding and blocks a-syn mediated inhibition of PLD2 (Okochi et al., 2000; Payton et al., 2004; Pronin et al., 2000) , an enzyme involved in the hydrolysis of phosphati dylcholine and vesicular trafficking.
Recent studies by McFarland and colleagues demonstrated that phosphorylation at S129 and Y125 constitute an important switch for regulating a-syn interaction with other proteins. They explored the role of phosphorylation at S129 or Y125 in protein-protein interactions involving a-syn by comparing the protein-protein interac tions of phosphorylated and non-phosphorylated C-terminal peptides encompassing these residues (residues 101-140) using pull down assays and mass spectrometry (McFarland et al., 2008) . Their studies showed great differences in the set of proteins pulled down by phosphorylated forms of a-syn. The phosphorylated peptides showed preferential interactions with pre-synaptic cytos keletal proteins and proteins involved in synaptic vesicle endocytosis, subunits of serine/threonine 140 kinases and phosphatases, whereas the non-phos phorylated peptide interacted preferentially with mitochondrial electron transport chain complexes. Some of the proteins reported to interact with a-syn [e.g. 14-3-3 and microtubule-associated pro tein 1B (MAP1B)] show a preference to the phos phorylated state (S129-P) of a-syn.
The NAC region in a-syn plays an important role in mediating a-syn fibrillization Waxman and Giasson, 2008) , mem brane binding (Lotharius and Brundin, 2002) and interactions with other proteins, such as the enzyme PLD2 (Payton et al., 2004) . Recent stu dies from our laboratory show that S87 phosphor ylation alters the conformation of membranebound a-syn and decreases its affinity to lipid vesicles, but does not abrogate binding, probably by destabilizing the helical conformation and decreasing the lipid-binding affinity of the protein around the phosphorylation site. Together, these findings underscore the fact that elucidating the role of post-translational modifications in the pathogenesis of a-syn will require a better under standing how these modifications alter the phy siologic and functional properties of the protein and how potential cross-talk between the differ ent modifications influences the function of a-syn in health and disease. Only an integrative inter disciplinary approach with standardized methods and measures for assessing changes in a-syn prop erties would bring us closer to answering the key outstanding mechanistic questions regarding the role of a-syn post-translational modification in PD and translate this knowledge into novel therapies. 
